Gritstone and bluebird bio enter cell therapy partnership
Gritstone Oncology agreed to use its EDGE personalized neoantigen platform to provide ten tumor-specific targets (and T-cell receptors (TCRs) directed to those targets) for cell therapy and gene editing firm bluebird bio Inc.
- Artificial Intelligence
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.